Summary
[3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin was used as a radioligand for the autoradiographic measurements of dopamine D3 receptors in rat and human brain. Preincubation of the brain sections was necessary to obtain binding of the radioligand in the islands of Calleja and in the nucleus accumbens, but not in cerebellar lobules 9/10 of the rat. D3 receptors were also totally occluded in unwashed sections of the human striatum. The radioligand binding to D3 receptors was maximal after preincubating the sections for at least 10 min. Pretreatment of the animals with reserpine or tetrabenazine, which results in a severe depletion of endogeneous monoamines, strongly reduces the occlusion of D3 receptors in unwashed brain sections. The occlusion of dopamine D3 receptors in brain sections suggests that thein vivo access to D3 receptors may be locally inhibited by endogenous dopamine.
Thein vitro binding affinities of 12 antipsychotic drugs for D2 and D3 receptors were evaluated in competition binding experiments, using both rat and cloned human receptors. Most of the compounds showed only a slightly lower affinity for D3 than for D2 receptorsin vitro. Affinities of the antipsychotic drugs for cloned human D2L and D3 receptors were very close to their affinities for the rat receptors.In vivo occupancy of these receptors in the rat brain was measuredex vivo by quantitative autoradiography, 2 hours after subcutaneous drug administration. For most compounds, occupancy of D3 receptors, as compared to D2 receptor occupancy, was lower than expected from the correspondingin vivo affinity ratios. For the new antipsychotic risperidone,in vivo occupancy of D3 receptors was measured both in the islands of Calleja and in the cerebellar lobules 9/10. This compound was three times less potent for the occupancy of D3 receptors in the islands of Calleja than in the cerebellum, an area lacking endogenous dopamine (ED50=28 and 10 mg kg−1, respectively).
Based on the observations in the rat brain, it may reasonably be supposed that therapeutic dosages of antipsychotic drugs will induce in patients only a minor occupancy of D3 receptors in brain areas containing high dopamine concentrations. The role of dopamine D3 receptors as a target of antipsychotic drugs may therefore be less important than previously thought.
Similar content being viewed by others
References
Bouthenet, M. L., Martres, M. P., Sales, N. &Schwartz, J. C. (1987) A detailed map** of dopamine D2 receptors in rat central nervous system by autoradiography with [125]iodosulpride.Neuroscience,20, 117–55.
Bouthenet, M. L., Souil, E., Martres, M. P., Sokoloff, P., Giros, B. &Schwartz, J. C. (1991) Localization of dopamine D3 receptor mRNA in the rat brain usingin situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA.Brain Res. 564, 203–19.
Cheng, Y. C. &Prusoff, W. H. (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction.Biochem. Pharmacol. 22, 3099–108.
Herroelen, L., de Backer, J.-P., Wilczak, N., Flamez, A., Vauquelin, G. &De Keyser, J. (1994) Autoradiographic distribution of D3-type dopamine receptors in human brain using [3H7-hydroxy-N,N-di-n-propyl-2-amino-tetralin.Brain Res. 648, 222–8.
Kebabian, J. W. &Calne, D. B. (1979) Multiple receptors for dopamine.Nature,227, 93–6.
Kung, M.-P., Kung, H., Chumpradit, S. &Foulon, C. (1993)In vitro binding of a novel dopamine D3 receptor ligand: [125I]trans-7-OH-PIPAT.Eur. J. Pharmacol. 235, 165–6.
Landwehrmeyer, B., Mengod, G. &Palacios, J. M. (1993) Dopamine D3 receptor mRNA and binding sites in human brain.Mol. Brain Res. 18, 187–92.
Lévesque, D., Diaz, G., Pilon, C., Martres, M.-P., Giros, B., Souil, E., Schott, D., Morgat, J.-L., Schwartz, J.-C. &Sokokoff, P. (1992) Identification, characterization, and localization of the dopamine D3 receptor in rat brain using [3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin.Proc. Natl. Acad. Sci. USA 89, 8155–9.
Leysen, J. E., Gommeren, W. &Laduron, P. M. (1978) Spiperone, a ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics ofin vitro receptor binding.Biochem. Pharmacol. 27, 307–16.
Leysen, J. E., Wynants, J., Eens, A. &Janssen, P. A. J. (1989) Ketanserin reduces a particular monamine pool in peripheral tissues.Mol. Pharmacol. 35, 375–80.
Mengod, G., Villaro, M. T., Landwehrmeyer, G. B., Mertinez-Mir, M. I., Sunahara, R. K., Seeman, P., O'Dowd, B. F., Probst, A. &Palacios, J. M. (1992) Visualization of dopamine D1, D2 and D3 receptor mRNA's in human and rat brain.Neurochem. Int. 20, 33S-43S.
Murray, A. M., Ryoo, H. &Joyce, J. N. (1992) Visualization of dopamine D3-like receptors in human brain with [125I]epidepride.Eur. J. Pharmacol. 227, 443–5.
Oestreicher, E. G. &Pinto, G. F. (1987) A microcomputer program for fitting enzyme inhibition equations.Comput. Biol. Med. 17, 317–21.
Paxinos, G. &Watson, C. (1986)The Rat Brain in Stereotaxic Coordinates. 2nd edn. Sydney: Academic Press.
Ramm, P. (1994) Advanced image analysis systems in cell, molecular and neurobiology applications.J. Neurosci. Meth. 54, 131–49.
Schotte, A., De Bruykere, K., Janssen, P. F. M. &Leysen, J. E. (1989) Receptor occupancy by ritanserin and risperidone measured byex vivo autoradiography.Brain Res. 500, 295–301.
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., &Leysen, J. E. (1992) Evidence for the occlusion of rat brain dopamine D3 receptorsin vivo.Eur. J. Pharmacol. 218, 373–5.
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., De Loore, K. &Leysen, J. E. (1996) Risperidone compared with new and reference antipsychotic drugs:in vitro andin vivo receptor binding.Psychopharmacol. 124, 57–73.
Schwartz, J. C., Lévesque, D., Martres, M. P. &Sokoloff, P. (1993) Dopamine D3 receptor: Basic and clinical aspects.Clin. Neuropharmacol. 16, 295–314.
Seeman, P. (1981) Brain dopamine receptors.Pharmacol. Rev. 32, 229–313.
Sokoloff, P., Giros, B., Martres, M. P., Bouthenet, M. L. &Schwartz, J. C. (1990) Molecular cloning and characterisation of a novel dopamine receptor (D3) as a target for neuroleptics.Nature 347, 146–50.
Stoof, J. C. &Kebabian, J. W. (1984) Two dopamine receptors: biochemistry, physiology and pharmacology.Life Sci. 35, 2281–96.
Sunahara, R. K., Guan, H. C., O'dowd, B. F., Seeman, P., Laurier, L. G., Ng, G., George, S. R., Torchia, J., van Tol, H. H. M. &Niznik, H. B. (1991) Cloning of a gene of human dopamine D5 receptor with higher affinity for dopamine than D1.Nature 350, 614–9.
Van Rossum, J. M. (1966) The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs.Arch. Int. Pharmacodyn. Ther. 160, 492–4.
Van Tol, H. H. M., Bunzow, J. R., Guan, H. C., Sunahara, R. K., Seeman, P., Niznik, H. B. &Civelli, O. (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine.Nature 350, 610–4.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schotte, A., Janssen, P.F.M., Bonaventure, P. et al. Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study. Histochem J 28, 791–799 (1996). https://doi.org/10.1007/BF02272152
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02272152